Skip to main content
Purple Biotech Ltd. logo

Purple Biotech Ltd. — Investor Relations & Filings

Ticker · PPBT ISIN · IL0007650166 TA Manufacturing
Open in API
Filings indexed 1,071 across all filing types
Latest filing 2023-10-31 Regulatory Filings
Country IL Israel
Listing TA PPBT

About Purple Biotech Ltd.

https://purple-biotech.com/

Purple Biotech Ltd. is a clinical-stage company that develops first-in-class therapies for cancer patients. The company focuses on advancing treatments designed to overcome tumor immune evasion and drug resistance, with the goal of providing effective and durable therapeutic solutions.

Recent filings

Filing Released Lang Actions
FORM D Notice of Exempt Offering of Securities
Regulatory Filings Classification · 98% confidence The document explicitly displays the header "UNITED STATES SECURITIES AND EXCHANGE COMMISSION" and the form title "FORM D". Form D is the standard SEC filing used to notify the SEC of an exempt offering of securities under Regulation D. This filing type is not explicitly listed in the provided definitions (AGM-R, 10-K, AR, etc.). According to Rule 3: 'Regulatory Filings' is the fallback for documents that do not neatly fit anywhere else. Therefore, the most appropriate classification is RNS (Regulatory Filings).
2023-10-31 English
FORM D Notice of Exempt Offering of Securities
Capital/Financing Update Classification · 98% confidence The document explicitly mentions 'FORM D Notice of Exempt Offering of Securities' and references the 'Israel Securities Authority' and 'Tel Aviv Stock Exchange'. Form D is a specific SEC filing used to notify the SEC of a sale of securities that qualifies for an exemption from registration under the Securities Act of 1933. This type of filing relates to fundraising or capital structure changes, specifically an offering of securities. Given the options, 'Capital/Financing Update' (CAP) is the most appropriate classification for a Form D filing, as it directly concerns the offering of securities for capital purposes. The document is the filing itself, not an announcement of a report, and it is highly specific, ruling out the general 'RPA' or 'RNS' categories.
2023-10-31 English
FORM F-1 - REGISTRATION STATEMENT
Regulatory Filings Classification · 100% confidence The document explicitly identifies itself as a "FORM F-1 REGISTRATION STATEMENT *UNDER THE SECURITIES ACT OF 1933*" and contains a "PROSPECTUS" section detailing the resale of American Depositary Shares by selling shareholders. A Form F-1 is the standard registration statement required by the SEC for foreign private issuers registering securities for public offering or resale in the U.S. While it is a registration document, the core purpose described (resale of securities) and the structure align most closely with documents related to capital raising or initial public offerings/major secondary offerings, which often utilize a prospectus. Among the provided codes, there isn't a specific code for a general SEC Registration Statement (like S-1 or F-1). However, the document is fundamentally about the offering and registration of securities for sale. Since it is a comprehensive registration document that includes a prospectus, and it is not a periodic report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A), the closest fit among the options that relates to securities offerings and capital structure is 'Capital/Financing Update' (CAP), although 'Regulatory Filings' (RNS) is a possibility if we treat F-1 as a general regulatory filing. Given the detailed nature of the prospectus and the focus on the offering/resale of shares, it is a primary capital markets document. Since Form F-1 is a registration statement, and the definitions do not explicitly cover registration statements, I must choose the best fit. Form F-1 is used to register securities for sale. This is a core financing activity. If the document were a simple announcement of a financing, CAP would fit. Since it is the actual registration document enabling the sale, and no better fit exists, I will lean towards the category that covers financing activities, or the general regulatory fallback. Given the context of financial reporting databases, registration statements are often categorized separately or under a broad 'Offering' or 'Financing' umbrella. 'CAP' (Capital/Financing Update) is the most relevant category describing the *purpose* of the filing (registering shares for sale). I will assign a high confidence score because the document type (Form F-1 Registration Statement/Prospectus) is explicitly stated.
2023-10-30 English
FORM F-1 - REGISTRATION STATEMENT
Regulatory Filings Classification · 95% confidence The document is an 'Immediate report on other matter' from PURPLE BIOTECH LTD, filed with the Israel Securities Authority and the Tel Aviv Stock Exchange. The core content discusses the submission of a draft Registration Statement on Form F-1 to the SEC and ISA. This is a regulatory filing concerning a specific corporate action (US listing/offering documentation submission) that doesn't fit neatly into the defined categories like 10-K, ER, or CAP. Since it is a general regulatory announcement that doesn't fit a more specific code, the fallback category 'Regulatory Filings' (RNS) is the most appropriate classification, especially given the reference to the ISA/TASE reporting system (MAGNA). The document length is short (2554 chars) and it announces the filing of another document (the F-1), which aligns with the spirit of an RNS or RPA, but RNS is broader for general regulatory notices.
2023-10-30 English
6K: Purple Biotech Announces Closing of $5Million Registered Direct Offering
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filing submitted to the SEC by Purple Biotech Ltd. It serves as an official announcement regarding the closing of a $5 million registered direct offering of American Depositary Shares (ADSs) and the issuance of warrants. While it contains a press release, the primary purpose of the 6-K filing is to report on capital-raising activities and financing updates. Therefore, it is classified as a Capital/Financing Update.
2023-10-19 English
6K: Purple Biotech Announces Closing of $5Million Registered Direct Offering
Capital/Financing Update Classification · 98% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority and the Tel Aviv Stock Exchange, referencing a '6K' filing (which is often used for foreign private issuers reporting material events, similar to an 8-K in the US context). The core content announces the 'Closing of $5Million Registered Direct Offering'. This event directly relates to the company's fundraising and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). Although it mentions an attached PDF, the primary purpose is the announcement of the financing event itself, not just the publication of a report.
2023-10-19 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.